Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Cancer Research and Clinical Oncology

• Publication date

  2017-06-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00432-017-2457-8PMID 28624910PMCID PMC11819458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

  2016cited by this paper
• Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells

  2016cited by this paper
• Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.

  2016cited by this paper
• Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics

  2015cited by this paper
• Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.

  2015cited by this paper
• Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study

  2015cited by this paper
• Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

  2015cited by this paper
• Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.

  2015cited by this paper
• Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies

  2014cited by this paper
• A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

  2014cited by this paper
• Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia

  2014cited by this paper
• First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

  2013cited by this paper
• Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study

  2013cited by this paper
• Targeting ribonucleotide reductase for cancer therapy

  2013cited by this paper
• Development of ribonucleotide reductase inhibitors: a review on structure activity relationships.

  2013cited by this paper
• A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors

  2013cited by this paper
• A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.

  2012cited by this paper
• A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

  2012cited by this paper
• Clinical Experience with Fludarabine in Leukaemia

  2012cited by this paper
• Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study

  2012cited by this paper
• Ribonucleotide Reductase Inhibitors: A New Look at an Old Target for Radiosensitization

  2012cited by this paper
• Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

  2012cited by this paper
• A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

  2012cited by this paper
• Hepatocellular carcinoma detection by gallium scan and subsequent treatment by gallium maltolate: rationale and case study.

  2011cited by this paper
• Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies

  2011cited by this paper
• Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma

  2011cited by this paper
• A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

  2011cited by this paper
• A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.

  2011cited by this paper
• Phase 2 trial of concurrent 5‐fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity‐modulated radiation therapy for locally advanced head and neck cancer

  2011cited by this paper
• Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

  2011cited by this paper
• Phase I and Pharmacokinetic Study of IV Vinflunine in Combination with Gemcitabine for Treatment of Advanced Non-small Cell Lung Cancer in Chemonaive Patients

  2011cited by this paper
• Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia

  2011cited by this paper
• Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.

  2011cited by this paper
• Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization

  2011cited by this paper
• Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.

  2011cited by this paper
• Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer

  2011cited by this paper
• A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

  2011cited by this paper
• A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

  2011cited by this paper
• Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

  2010cited by this paper
• A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells.

  2010cited by this paper
• Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.

  2010cited by this paper
• Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia

  2010cited by this paper
• A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

  2010cited by this paper
• Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.

  2010cited by this paper
• Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.

  2010cited by this paper
• A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine

  2010cited by this paper
• Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

  2010cited by this paper
• Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia.

  2010cited by this paper
• Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors

  2009cited by this paper
• A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer.

  2009cited by this paper
• The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

  2009cited by this paper
• A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

  2009cited by this paper
• 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

  2009cited by this paper
• Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma.

  2009cited by this paper
• The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

  2009cited by this paper
• Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.

  2009cited by this paper
• Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

  2009cited by this paper
• Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B‐cell non‐Hodgkin lymphoma

  2009cited by this paper
• Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd).

  2009cited by this paper
• Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.

  2009cited by this paper
• A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia

  2009cited by this paper
• Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non‐Hodgkin lymphoma

  2009cited by this paper
• Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

  2009cited by this paper
• Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia

  2009cited by this paper
• Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma

  2009cited by this paper
• Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

  2009cited by this paper
• Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.

  2009cited by this paper
• Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results.

  2008cited by this paper
• Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.

  2008cited by this paper
• A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

  2008cited by this paper
• Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia

  2008cited by this paper
• A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma

  2008cited by this paper
• Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.

  2008cited by this paper
• A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149)

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

  2008cited by this paper
• Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.

  2008cited by this paper
• A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells

  2008cited by this paper
• A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

  2008cited by this paper
• Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.

  2008cited by this paper
• Hydroxyurea for the treatment of sickle cell anemia.

  2008cited by this paper
• Sequential Oral Hydroxyurea and Intravenous Cytosine Arabinoside in Refractory Childhood Acute Leukemia: A Pediatric Oncology Group Phase 1 Study

  2008cited by this paper
• Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)

  2007cited by this paper
• Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study

  2007cited by this paper
• A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.

  2007cited by this paper
• Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.

  2007cited by this paper
• Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer

  2007cited by this paper
• Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.

  2007cited by this paper
• Inaugural Article: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA

  2007cited by this paper
• Phase I Trial of Motexafin Gadolinium in Combination with Docetaxel and Cisplatin for the Treatment of Non-small Cell Lung Cancer

  2007cited by this paper
• Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.

  2007cited by this paper
• Development of Gallium Compounds for Treatment of Lymphoma: Gallium Maltolate, a Novel Hydroxypyrone Gallium Compound, Induces Apoptosis and Circumvents Lymphoma Cell Resistance to Gallium Nitrate

  2007cited by this paper
• Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

  2007cited by this paper
• RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo

  2007cited by this paper
• Bortezomib for the Treatment of Mantle Cell Lymphoma

  2007cited by this paper
• Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

  2007cited by this paper

• Pyrimidine nucleoside analogues and antitumour drugs based on them: fifty years in therapy

  2026cites this paper
• Discovery of a novel non-toxic analog of clofarabine for the treatment of triple negative breast cancer.

  2025cites this paper
• Exploring the Use of Intracellular Chelation and Non-Iron Metals to Program Ferroptosis for Anticancer Application

  2024cites this paper
• New Insights into Aspirin’s Anticancer Activity: The Predominant Role of Its Iron-Chelating Antioxidant Metabolites

  2024cites this paper
• Significance of Ribonucleoside-diphosphate Reductase Subunit M2 in Lung Adenocarcinoma.

  2024cites this paper
• Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells

  2023influential citation
• ORAOV1, CCND1, and MIR548K Are the Driver Oncogenes of the 11q13 Amplicon in Squamous Cell Carcinoma

  2023cites this paper
• From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia

  2023cites this paper
• Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects

  2023cites this paper
• The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers

  2022cites this paper
• Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer

  2022cites this paper
• Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics.

  2022cites this paper
• New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer

  2022cites this paper
• Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment

  2022cites this paper
• Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present

  2022cites this paper
• Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine

  2022cites this paper
• Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation

  2021cites this paper
• Cancer interception by interceptor molecules: mechanistic, preclinical and human translational studies with chlorophylls

  2021cites this paper
• Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells

  2021cites this paper
• Iron Chelator Transmetalative Approach to Inhibit Human Ribonucleotide Reductase

  2021cites this paper
• Triapine Analogues and Their Copper(II) Complexes: Synthesis, Characterization, Solution Speciation, Redox Activity, Cytotoxicity, and mR2 RNR Inhibition.

  2021cites this paper
• E. coli Ribonucleotide Reductase β2 Subunit Inactivation by Triapine Occurs through Binding of a Triapine-Fe(II) Adduct.

  2021cites this paper
• Cell-Penetrating Peptide and siRNA-Mediated Therapeutic Effects on Endometriosis and Cancer In Vitro Models

  2021influential citation
• Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective

  2021cites this paper
• Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine

  2021cites this paper
• Gated Proton Release during Radical Transfer at the Subunit Interface of Ribonucleotide Reductase.

  2020cites this paper
• The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors

  2020cites this paper
• Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.

  2020cites this paper
• Overexpression of ribonucleotide reductase small subunit, RNRM, increases cordycepin biosynthesis in transformed Cordyceps militaris.

  2020cites this paper
• RRM2 elicits the metastatic potential of breast cancer cells by regulating cell invasion, migration and VEGF expression via the PI3K/AKT signaling.

  2020cites this paper
• Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells.

  2020cites this paper
• Ribonucleotide Reductases: Structure, Chemistry, and Metabolism Suggest New Therapeutic Targets.

  2020cites this paper
• Delivery of Natural Products Using Polymeric Particles for Cancer Chemotherapeutics

  2020cites this paper
• Sustainable Agriculture Reviews 43: Pharmaceutical Technology for Natural Products Delivery Vol. 1 Fundamentals and Applications

  2020cites this paper
• Novel Triapine Derivative Induces Copper-Dependent Cell Death in Hematopoietic Cancers.

  2019cites this paper
• Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β-catenin signaling pathway

  2019cites this paper
• Metal-free ribonucleotide reduction powered by a DOPA radical in Mycoplasma pathogens

  2018cites this paper
• Inhibition of breast cancer cell growth by the combination of clofarabine and sulforaphane involves epigenetically mediated CDKN2A upregulation

  2018cites this paper
• Metal-independent ribonucleotide reduction powered by a DOPA radical in Mycoplasma pathogens

  2018cites this paper
• Design, synthesis and in vitro evaluation of new thiosemicarbazone derivatives as potential anticancer agents

  2018cites this paper
• Novel Clofarabine-Based Combinations with Polyphenols Epigenetically Reactivate Retinoic Acid Receptor Beta, Inhibit Cell Growth, and Induce Apoptosis of Breast Cancer Cells

  2018cites this paper
• An Animal Model for Assessing the Effects of Hydroxyurea Exposure Suggests That the Administration of This Agent to Pregnant Women and Young Infants May Not Be as Safe as We Thought

  2018cites this paper
• Drug Repurposing for the Treatment of Acute Myeloid Leukemia

  2017cites this paper